oral CDK8 kinase inhibitor
effective in ovariectomized rat model
CDK8 identified as MoA after screen
Bioorganic & Medicinal Chemistry Letters
Daiichi Sankyo Co. Ltd.
DS96432529
1 min read
7. The Daiichi Sankyo CDK8 kinase inhibitor, DS96432529, is intended to be a bone anabolic agent. The molecule shows preclinical efficacy and synergy with alendronate or parathyroid hormone. The discovery program was initiated well before the likely target (CDK8) was identified and provides an interesting retrospective case study for phenotypic drug discovery.
Search By Structure
- Paxlovid
- GS-621763
- ASP2453
- SY-5609
- BIIB091
- “compound Ia”
- DS96432529
- “compound 27”
- tepotinib
- PF-06939999
- “compound 5”
- compound 59
- M5717
- compound 1
Molecules of the Month
2023
2022
2021
2020